Sign In

New Canadian opioid prescribing guidelines development: Have your say

​As you know, we are all deeply concerned about the potential harms of opioids and other psychoactive prescription medications. As prescribers, we have a fundamental role in helping to ensure the safe and effective use of this medication, and to deter its abuse.

This is why the CMA is actively participating in the Pan-Canadian Collaborative for Safe Prescribing. New Canadian opioid guidelines are being developed and you can provide feedback right now until February 28 by clicking here.

A final version of the guidelines is expected for March 2017. The CMA will be watching closely and will consult with membership to assess the feasibility of implementation of the guidelines.

Opioid prescribing is only one piece of the issue and no one group can address the issue alone. This is why we will continue to work with other medical and governmental partners, including participating in the Pan-Canadian Collaborative for Safe Prescribing and the Executive Council of the First Do No Harm strategy. The goal is to develop solutions to the crisis, specifically a comprehensive national strategy to reduce the negative outcomes associated with opioids in Canada.

 

Forward any comments about this article to: cmanews@cma.ca.